Success Metrics

Clinical Success Rate
50.0%

Based on 3 completed trials

Completion Rate
50%(3/6)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
3(50%)

Phase Distribution

Ph phase_1
4
67%
Ph phase_2
1
17%
Ph not_applicable
1
17%

Phase Distribution

4

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
4(66.7%)
Phase 2Efficacy & side effects
1(16.7%)
N/ANon-phased studies
1(16.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

3 of 6 finished

Non-Completion Rate

50.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

6

all time

Status Distribution
Completed(3)
Terminated(3)

Detailed Status

Terminated3
Completed3

Development Timeline

Analytics

Development Status

Total Trials
6
Active
0
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 14 (66.7%)
Phase 21 (16.7%)
N/A1 (16.7%)

Trials by Status

terminated350%
completed350%

Recent Activity

0 active trials
Showing 5 of 6
completedphase_1

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

NCT00217373
terminatedphase_1

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

NCT00088933
completednot_applicable

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

NCT00091039
completedphase_2

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

NCT00052351
terminatedphase_1

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

NCT00009958
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT00217373Phase 1

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

Completed
NCT00088933Phase 1

Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer

Terminated
NCT00091039Not Applicable

Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery

Completed
NCT00052351Phase 2

Vaccine Therapy Plus Sargramostim and Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer

Completed
NCT00009958Phase 1

Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer

Terminated
NCT00048893Phase 1

Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer

Terminated

All 6 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
6